Novotech Partners with Kyungpook National University Hospital to Strengthen Clinical Trial Capabilities in South Korea
Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provider of Site Management Organization (SMO) services have entered into a strategic partnership by signing a Memorandum of Understanding (MOU) with Kyungpook National University Hospital (KNUH). The partnership will support clinical trials across KNUH’s prestigious institutions including the Advanced Clinical Trials Center, the KNUH main campus, and the Chilgok KNUH in South Korea.
This collaboration is a key milestone for the advanced clinical trials in South Korea, strategically aligning with the amendments to the Advanced Regenerative Bio Act. This agreement builds upon the recent inauguration of KNUH’s Advanced Clinical Trials Center opened in November last year, marking its first official partnership post-amendment of the Bio Act.
The amendments to the Advanced Regenerative Bio Act expanded the scope of advanced regenerative medicine, allowing the use of investigational therapies in clinical trials and expanding the number of authorized regenerative medicine institutions. Previously limited to severe, rare, and incurable diseases, regenerative medicine applications will now extend to a broader range of conditions, including general diseases.
Patients outside of clinical trials will also gain access to regenerative medicine services, while the range of applicable technologies—including cell and gene therapies (CGT) and tissue engineering—has significantly expanded.
Under the previous framework, CGTs required formal drug approval for clinical application. With these regulatory changes, CGTs in clinical trials can now be utilized upon review committee approval, streamlining access to innovative therapies.
The partnership creates a comprehensive framework across KNUH’s network with early-stage clinical trials primarily conducted at the Advanced Clinical Trials Center, while late-stage trials will be managed with the KNUH’s hospital system itself.
Speaking at the ceremony, Prof. Hyungran Yoon, Director of the Advanced Clinical Trials Center, spoke about the benefits of the collaboration, “The Advanced Clinical Trials Center will oversee trials for all diseases treated at KNUH, strengthening our role as a leader in clinical research and regenerative medicine. The partnership agreement with Novotech will expand their capacity to offer innovative treatment opportunities both domestically and internationally.”
Dr. Yooni Kim, Managing Director, Asia-Pacific at Novotech, highlighted the strategic advantages. “This partnership combines Novotech’s global expertise with KNUH’s specialized capabilities to offer cutting-edge treatment solution and streamlined trial operations. By leveraging this synergy, we aim to boost South Korea’s position on the global stage in regenerative medicine and enhance clinical trial excellence worldwide.”
This partnership also marks a significant milestone for Acrostar, Novotech’s SMO services provider. Daniel Kim, Director of Acrostar Asia-Pacific, shared his excitement about the partnership, “This is Acrostar’s first partnership in South Korea. Through this collaboration, we will actively support the site and ensure the smooth progress of clinical trials from a site management perspective.”
This strategic partnership means a shared commitment to advancing clinical research in South Korea and contributing to the global development of regenerative medicine and advanced clinical trials.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317570511/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 20265.11.2025 10:30:00 CET | Press release
First-ever no-alcohol beer sponsor of Olympic Winter Games celebrates “For Every Golden Moment” platform with consumers globally As the 100-day countdown to the Olympic Winter Games continues, and in a year the global Corona brand is celebrating its 100th anniversary, Corona Cero is officially set to bring golden moments to the slopes of Milano Cortina 2026. As the first no-alcohol beer sponsor of the Winter Olympics, the brand is revving up its “For Every Golden Moment” global platform to invite consumers to celebrate every golden moment any time, any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105994873/en/ Corona Cero's "For Every Golden Moment" Olympic Winter Games What began at the Olympic Games Paris 2024, Corona Cero’s Olympics partnership reinforces that beer and sports are better together by offering consumers more choices for any occasion. Corona Cero’s role reflects AB InBev and the International Oly
Nissan and Infobip Achieve 200% Increase in Engagement with AI-Driven WhatsApp Campaign5.11.2025 10:00:00 CET | Press release
AI-powered voice game sets new standard for digital marketing Nissan has redefined customer engagement by partnering with global cloud communications platform Infobip to pioneer a first-of-its-kind Agentic AI campaign. Nissan Kingdom of Saudi Arabia (KSA) leveraged Infobip’s newly launched Conversational AI Gamification, an AI-powered toolset that enables playful, immersive experiences across messaging channels. The marketing campaign utilized Infobip's Vocalize feature, an AI-powered voice game where users competed to win a brand-new Nissan Magnite. Participants used their voices to match an audio waveform to the outline of a car, directly within WhatsApp. This innovative approach transformed lead generation into an engaging competition, driving user participation and brand interaction. For Nissan KSA, the campaign enhanced brand awareness, increased engagement time, simplified lead acquisition, and stronger brand affinity. The innovative format also provided a cost-effective acquisit
NHOA Energy Commissions a 50 MWh Energy Storage System in Sicily5.11.2025 08:45:00 CET | Press release
The Vicari BESS, supplied on a turnkey EPC basis, integrates advanced storage technologies with two of ERG’s onshore wind farms, strengthening Sicily’s role in Italy’s energy transition NHOA Energy, a global provider of utility-scale energy storage systems, announces the commissioning of a 50 MWh Battery Energy Storage System (BESS) in Vicari, Sicily. Developed for ERG, a leading international independent renewable power producer, this project marks a major milestone in the deployment of large-scale storage systems supporting grid stability and renewable energy integration. Located at ERG’s substation connected to the Vicari and Roccapalumba wind farms, the system has a power capacity of 12.5 MW and a nominal storage capacity of 50 MWh, enabling it to store renewable energy for up to four hours. Fully designed, built, and commissioned by NHOA Energy as both BESS supplier and EPC (Engineering, Procurement and Construction) contractor, the project integrates proprietary Power Conversion
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile5.11.2025 07:00:00 CET | Press release
This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types1,2 Galderma’s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide3,4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocainefor augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also
The Estée Lauder Companies Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders5.11.2025 02:08:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces the pricing of the previously announced registered public offering (the “Offering”) of the Company’s Class A Common Stock, par value $.01 per share, by trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) at a price to the public of $90 per share. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Offering is expected to close on November 6, 2025, subject to the satisfaction of customary closing conditions. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom